STOCK TITAN

Regeneron Pharmaceuticals, Inc. - REGN STOCK NEWS

Welcome to our dedicated news page for Regeneron Pharmaceuticals (Ticker: REGN), a resource for investors and traders seeking the latest updates and insights on Regeneron Pharmaceuticals.

Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect Regeneron Pharmaceuticals's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.

Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of Regeneron Pharmaceuticals's position in the market.

Rhea-AI Summary
Regeneron and Intellia Therapeutics announce an expanded research collaboration to develop CRISPR-based gene editing therapies for neurological and muscular diseases. The collaboration will leverage Regeneron's proprietary antibody-targeted viral vector delivery technologies and Intellia's Nme2Cas9 gene editing systems.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.19%
Tags
none
-
Rhea-AI Summary
Regeneron Pharmaceuticals announces FDA acceptance for Priority Review of odronextamab for the treatment of lymphoma.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.39%
Tags
none
-
Rhea-AI Summary
Regeneron Pharmaceuticals to report Q3 2023 financial results on November 2, 2023
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.39%
Tags
conferences earnings
Rhea-AI Summary
Regeneron Pharmaceuticals and Sanofi's supplemental Biologics License Application for Dupixent to treat children aged 1 to 11 with eosinophilic esophagitis (EoE) has been accepted for Priority Review by the FDA. The target action date for the FDA decision is January 31, 2024. Dupixent is currently the only approved treatment for children and adults aged 12 years and older with EoE. The sBLA is supported by positive data from the Phase 3 EoE KIDS trial, showing Dupixent's efficacy and safety in children aged 1 to 11 with EoE. Safety results were consistent with the known safety profile of Dupixent. Priority review is granted to therapies that have the potential to provide significant improvements in the treatment of serious conditions.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.27%
Tags
none
-
Rhea-AI Summary
Regeneron completes acquisition of Decibel Therapeutics, strengthening gene therapy and auditory programs.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.19%
Tags
-
Rhea-AI Summary
AbCellera expands collaboration with Regeneron, increasing the number of targets from 4 to 8.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
none
Rhea-AI Summary
Regeneron Pharmaceuticals announces CFO retirement and successor
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
none
-
Rhea-AI Summary
Regeneron Pharmaceuticals announces the addition of Kathryn Guarini and David P. Schenkein to its Board of Directors. Guarini brings technology and business experience, while Schenkein has expertise in oncology and hematology. Marc Tessier-Lavigne has retired from the Board.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
management
-
Rhea-AI Summary
Regeneron Pharmaceuticals to participate in upcoming healthcare conferences
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.14%
Tags
none
Rhea-AI Summary
Regeneron receives funding from BARDA for clinical development of next-generation COVID-19 monoclonal antibody therapy
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.44%
Tags
covid-19
Regeneron Pharmaceuticals, Inc.

Nasdaq:REGN

REGN Rankings

REGN Stock Data

99.30B
102.75M
2.58%
89.25%
1.3%
Pharmaceutical Preparation Manufacturing
Manufacturing
Link
United States
Tarrytown

About REGN

Regeneron Pharmaceuticals, Inc. is an American biotechnology company headquartered in Westchester County, New York. The company was founded in 1988.